SharePoint
A- A A+

Research & Education

Haematology-Oncology Research Group (HORG)

Haematology-Oncology Research Group (HORG)

​CANCER RESEARCH

The highest aspirations in the fight against cancer are of little worth unless we have the ability to deliver, and deliver well. This is crucial if the Haematology Oncology Research Group (HORG) is to succeed and become one of Asia's leading cancer research groups. 

One of the biggest challenges I have found is that you can have all the best aspirations to bring fantastic treatment to patients, but everything becomes secondary if you cannot execute these expectations. 

It allows us the proper framework to do the work that needs to be done. You need proper infrastructure because clinical research involves everything from negotiations with companies, ensuring that data is collected and entered at the highest levels of accuracy, and following all the international regulations and guidelines for safety, efficacy, and ethics. 

Professor John Eu-Li Wong
Chief Executive
National University Health System

Observations that drug toxicities were, at times, more severe in our Asian patients spurred this desire to learn more about the Asian phenotype. Since our early start to investigate areas such as this, we have grown strength to strength in developing our research capabilities and interests. From demonstrating that various chemotherapy regimens for common cancers like breast and lung may result in different levels of side effects as compared with Caucasians, we have developed the international recognition in drug development to lead first-in-man early drug studies. This has had the additional benefit of offering suitable patients the opportunity to utilise cutting-edge and novel new drugs, long before these become available for routine use.

Today, HORG is recognised as being at the forefront of translational research in cancer therapeutics. Our researchers have the support of a committed team of doctors, administrators, clinical trial coordinators, nurse and pharmacists, in conducting their research. This model has helped allow dedicated care for our patients on clinical trials, focusing much needed time and effort where it is necessary, i.e. the patient.

Professor John Eu-Li Wong
Chief Executive
National University Health System


​The Department of Haematology-Oncology was formerly known as the Department of Medical Oncology, that was originally formed in 1996. Today, the department is recognised as being at the forefront of translational research in cancer therapeutics. We aim to do better, from nurturing the next generation of investigators to continuing to help develop and increase our understanding of new therapies in Asia.



​The Haematology-Oncology Research Group (HORG) Trial Unit is headed by Ms Joanne Chio, who led a team responsible for conducting Phase I to III clinical trials in cancer. HORG conducts a number of first-in-man and first-in-class early drug studies.

HORG trial unit comprises of a dedicated team of clinical research coordinators, data coordinators, administrators and finance executives. It manages and supports all aspects of the clinical trial - from securing ethics, regulatory, budget and legal approvals to the conducting of the study.